It will be a major challenge for the future to proof the concept whether the reactivation of MYBBP1A expression could serve as a novel option for anti-cancer therapy for patients with advanced HNSCC and thereby ameliorate the therapy response rate. The gene discussed is MYBBP1A; the disease is cancer.